Live Breaking News & Updates on Sharvil patel

Stay informed with the latest breaking news from Sharvil patel on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Sharvil patel and stay connected to the pulse of your community

Zydus And Torrent Sign Licensing Agreement For Co-marketing Saroglitazar Mg

Zydus And Torrent Sign Licensing Agreement For Co-marketing Saroglitazar Mg
freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.

India , Sharvil-patel , Aman-mehta , Torrent-pharmaceuticals-ltd , Torrent-pharmaceuticals-limited , Zydus-lifesciences-ltd , Zydus-lifesciences , Zydus-lifesciences-limited , Non-alcoholic-steato-hepatitis , Non-alcoholic-fatty-liver-disease , Saroglitazar-magnesium , Semi-exclusive-co-marketing-agreement

Torrent, Zydus in co-marketing pact for liver disease drug Saroglitazar

Torrent Pharmaceuticals and Zydus Lifesciences formed a licensing and supply pact to co-market Saroglitazar Mg, the sole approved treatment for Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) in India. Under the agreement, Torrent gains semi-exclusive rights to market as VORXAR while Zydus continues marketing as Lipaglyn and Bilypsa. Licensing fees and milestone payments are part of the pact.

India , Zydus-lifescieces , Sharvil-patel , Zydus-lifesciences , Aman-mehta , Torrent-pharmaceuticals , Non-alcoholic-steato-hepatitis , Non-alcoholic-fatty-liver-disease , Saroglitazar-magnesium , Zydus , Saroglitazar , Saroglitazar-drug

Torrent, Zydus collaborate to bring liver disease treatment to India

Torrent, Zydus collaborate to bring liver disease treatment to India
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

India , Aman-mehta , Sharvil-patel , Torrent-pharmaceuticals , Zydus-lifesciences , Non-alcoholic-steatohepatitis , Non-alcoholic-fatty-liver-disease , Drug-controller-general , Managing-director , Saroglitazar-magnesium , Alcoholic-liver-disease ,

Torrent and Zydus sign licensing pact for co-marketing Saroglitazar Mg

Torrent and Zydus sign licensing pact for co-marketing Saroglitazar Mg
uniindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uniindia.com Daily Mail and Mail on Sunday newspapers.

India , Sharvil-patel , Zydus-lifesciences , Aman-mehta , Torrent-pharmaceuticals-ltd , Saroglitazar-mgnew-delhi , Torrent-pharma , Non-alcoholic-steato-hepatitis , Non-alcoholic-fatty-liver-disease , Saroglitazar-magnesium , Managing-director , Torrent-pharmaceuticals

India's Zydus Q2 profit jumps on strong domestic, US demand

Indian generic drugmaker Zydus Lifesciences Ltd reported a better-than-expected 53.3% jump in quarterly profit on Tuesday, led by the strong sales in the domestic market and the United States....

India , Sharvil-patel , Dhanya-ann-thoppil , Rishika-sadam , Cipla , Zydus-wellness-ltd , Director-sharvil-patel , Nifty-pharma , Markets ,

zydus: Zydus Q2 Results: Profit jumps on strong domestic, US demand

India's generic drug makers, which draw a significant share of revenue from the crucial U.S. market, are recovering from the effects of eroding prices in the largest drug market in the world.

India , United-states , Sharvil-patel , Zydus-lifesciences-ltd , Cipla , Zydus-wellness-ltd , Director-sharvil-patel , Nifty-pharma , Zydus , Strong-domestic , Us-demand , Jumps

Zydus Lifesciences Q2 Results: Firm reports 53% YoY jump in net profit at Rs 801 crore

Revenue from operations rose 9.1% YoY to Rs 4369 crore in Q2FY24 compared to Rs 4006 crore in Q2FY23. On QoQ revenue declined 15%. The earnings before interest, tax, depreciation and ammortisation (EBITDA) increased 40.6% YoY to Rs 1146 crore. On QoQ, EBITDA dropped 23.9%.

India , Sharvil-patel , Zydus-lifesciences , Zydus-lifesciences-q2-results , Zydus-lifesciences-q2 , Zydus-lifesciences-results , Zydus-lifesciences-q2-earnings ,

Zydus Lifesciences posts 53.3% jump in quarterly profit

India Business News: Indian pharmaceutical company Zydus Lifesciences reported a 53.3% increase in quarterly profit, driven by strong sales in the domestic and US markets.

India , United-states , Ahmedabad , Gujarat , Sharvil-patel , Zydus-lifesciences , Zydus-lifesciences-limited-on , Zydus-lifesciences-limited , Business-news , Total-revenue , Indian-pharma , Generic-drug-makers

Zydus Lifesciences Q2 profit rises 53 % at ₹801 crore

The company had posted a net profit of ₹522.5 crore for the same period last fiscal, Zydus Lifesciences said in a regulatory filing.

India , Sharvil-patel , Zydus-lifesciences , Lifesciences-managing-director-sharvil-patel , Q2-profit , Us-formulations ,

Zydus receives FDA approval for Zituvimettm, shares fall - The Hindu BusinessLine

Zydus receives FDA approval for Zituvimettm, shares fall - The Hindu BusinessLine
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

India , Sharvil-patel , Facebook , Linkedin , Drug-administration , Zydus-lifesciences , Twitter , Zydus-lifesciences-limited , New-drug-application , Granules-india , Managing-director , Esomeprazole-magnesium